CLL/SLL Treatment Timeline

Name: CLL/SLL Treatment Timeline
Creator: Kelly Casteel, MD

An interactive, clinician-facing chronicle of the trials that built modern CLL/SLL care — from the chlorambucil and FCR chemoimmunotherapy backbone through BTK inhibitors, BCL‑2 inhibition, and the fixed-duration, chemo-free era of all-oral combinations and CAR‑T. Click any drug to trace its Phase 1→3→approval lineage; click a trial for arms, endpoints, results, and FDA/EMA milestones.

Data verified against ClinicalTrials.gov & primary literature · last reviewed Jul 2026

View

Drug class

Trial phase

Ph 1 Ph 2 Ph 3

Status

Approved Investigational Withdrawn / failed

Activity

Ongoing only

NCCN

In NCCN v2.2026 Category 1 only

Reference

Solid outline = approved Dashed outline = investigational Dashed rose = withdrawn / failed Pulsing dot = ongoing trial ✓badge = FDA / EMA approved NCCN category badge (1 / 2A / biomarker) Ambient curve = rising survival as approvals accrue

Therapies covered in this timeline

An interactive timeline of CLL/SLL drug development — from chlorambucil to BTK inhibitors, venetoclax, and CAR-T — built from primary trials, ClinicalTrials.gov, and FDA records. By Dr. Kelly Casteel.

Chlorambucil
Fludarabine
FCR regimen
Bendamustine
Rituximab
Obinutuzumab
Ofatumumab
Allogeneic SCT
Idelalisib
Duvelisib
Ibrutinib
Acalabrutinib
Zanubrutinib
Venetoclax
Venetoclax + Ibrutinib
Venetoclax + Acalabrutinib
Pirtobrutinib
Nemtabrutinib
Epcoritamab
Mosunetuzumab
Lisocabtagene maraleucel

Enable JavaScript to explore the full interactive timeline — with trial arms, endpoints, results, and FDA/EMA approval dates for each therapy.

Scroll horizontally → · click a drug node to open its trial lineage

NCCN preferred regimens by line of therapy

Derived from NCCN Clinical Practice Guidelines in Oncology — Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026 (Mar 2026)

Preference tiers (Preferred / Other Recommended / Useful in certain circumstances) and Categories of Evidence (1, 2A) are summarised for reference and attributed to NCCN. This is not a reproduction of the guideline; consult the authoritative, current version at nccn.org. Click a drug chip to jump to that agent’s trial lineage. Biomarker-restricted (del(17p)/TP53) options are noted inline.